TP53 and Miyoshi myopathy: We observed an increased frequency of TP53 abnormalities in patients with ≥ 2 prior therapy lines, further supporting the concept that treatment pressure drives clonal evolution in MM, favouring the outgrowth of TP53-aberrant populations (Sreedharanunni et al. 2024; Martello et al. 2022; Chin et al. 2017; Jovanović et al. 2019; Kortüm et al. 2016).